Global #LifeScience #Patent Applications by Country of Origin, 1981-2011 http://t.co/ChTcwdRBc2 @JAMA_current http://t.co/H3OfwaMU4R
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Global #LifeScience #Patent Applications by Country of Origin, 1981-2011 http://t.co/ChTcwdRBc2 @JAMA_current http://t.co/H3OfwaMU4R
Performance of Publicly Traded #LifeSciences #HealthCare Companies, 2003-2013 http://t.co/7fl3GfbblB @JAMA_current http://t.co/MyHX01tcxl
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
If US does not wake up it will lose its scientific leadership pretty soon - scary prediction from @JAMA_current http://t.co/nSAhdWcE47
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
The Anatomy of Medical Research: US and International Comparison http://t.co/WpGNoVXQhH
The Anatomy of Medical ResearchUS and International Comparisons http://t.co/VKfbT4x5LO
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
The Anatomy of Medical Research http://t.co/zWZQmOBn9C
The US is losing its global lead in the medical research industry http://t.co/MJDcvyp4yF
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Cancer leads MT @JAMA_current @doctorfullerton Preferential areas of therapeutic development http://t.co/6g9OJ9ewB8 http://t.co/iVO0g4y6cr
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
US $ for health & medical research $117.2b, Australia $3.8b (ratio 31); US population 320m, Australia 24m (ratio 13) http://t.co/U0wUvhfa58
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
A foreboding trend http://t.co/ruZrCLHNZh @JAMA_current
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
#Migraine NIH research funding. No major disease is as underfunded. Almost off-the-charts. http://t.co/3bYdnTFkpW RT http://t.co/ZhnEuDin0K
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
The Anatomy of Medical Research http://t.co/FwRBiHiUxb
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
US $ for health & medical research $117.2b, Australia $3.8b (ratio 31); US population 320m, Australia 24m (ratio 13) http://t.co/U0wUvhfa58
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
From @JAMA_current -- "The Anatomy of Medical Research": http://t.co/DJY9CKTDqU
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
The Anatomy of Medical Research http://t.co/xsLAd3bJCc @JAMA_current
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
Rare diseases have emerged for industry as a preferential area of therapeutic development http://t.co/H8MlwDMtm9 http://t.co/nSS5ApQa7c
#Migraine NIH research funding. No major disease is as underfunded. Almost off-the-charts. http://t.co/3bYdnTFkpW RT http://t.co/ZhnEuDin0K
US $ for health & medical research $117.2b, Australia $3.8b (ratio 31); US population 320m, Australia 24m (ratio 13) http://t.co/U0wUvhfa58
RT @JAMA_current: 2004-2011: #Pharma funding spent on phase 3 clinical trials increased by 36% http://t.co/nquvnBxm5U http://t.co/3HjmWVRqJy
US $ for health & medical research $117.2b, Australia $3.8b (ratio 31); US population 320m, Australia 24m (ratio 13) http://t.co/U0wUvhfa58
If US does not wake up it will lose its scientific leadership pretty soon - scary prediction from @JAMA_current http://t.co/nSAhdWcE47
2004-2011: #Pharma funding spent on phase 3 clinical trials increased by 36% http://t.co/T7N1oafHiP http://t.co/7p76rYWt0U
US lead in medical innovation is decreasing. Report on economics of medical research. http://t.co/ZXeZxdRRDF #healthinnovations
US $ for health & medical research $117.2b, Australia $3.8b (ratio 31); US population 320m, Australia 24m (ratio 13) http://t.co/U0wUvhfa58
US $ for health & medical research $117.2b, Australia $3.8b (ratio 31); US population 320m, Australia 24m (ratio 13) http://t.co/U0wUvhfa58
US $ for health & medical research $117.2b, Australia $3.8b (ratio 31); US population 320m, Australia 24m (ratio 13) http://t.co/U0wUvhfa58
2004-2011: #Pharma funding spent on phase 3 clinical trials increased by 36% http://t.co/T7N1oafHiP http://t.co/7p76rYWt0U
If US does not wake up it will lose its scientific leadership pretty soon - scary prediction from @JAMA_current http://t.co/nSAhdWcE47
If US does not wake up it will lose its scientific leadership pretty soon - scary prediction from @JAMA_current http://t.co/nSAhdWcE47
The USA is 50 years ahead of actual time. http://t.co/nqZ20kmQZq
2004-2011: #Pharma funding spent on phase 3 clinical trials increased by 36% http://t.co/T7N1oafHiP http://t.co/7p76rYWt0U
“@JAMA_current: 2004-2011: #Pharma funding spent on phase 3 clinical trials increased by 36% http://t.co/SYt2HCB9iQ http://t.co/jynj3rF83v”
2004-2011: #Pharma funding spent on phase 3 clinical trials increased by 36% http://t.co/T7N1oafHiP http://t.co/7p76rYWt0U
2004-2011: #Pharma funding spent on phase 3 clinical trials increased by 36% http://t.co/T7N1oafHiP http://t.co/7p76rYWt0U
#Migraine NIH research funding. No major disease is as underfunded. Almost off-the-charts. http://t.co/3bYdnTFkpW RT http://t.co/ZhnEuDin0K
2004-2011: #Pharma funding spent on phase 3 clinical trials increased by 36% http://t.co/T7N1oafHiP http://t.co/7p76rYWt0U
Gloomy story JAMA-"The Anatomy of Medical Research"-US leadership in biomedical research being undermined. http://t.co/yxjFZIX49F
Gloomy story JAMA-"The Anatomy of Medical Research"-US leadership in biomedical research being undermined. http://t.co/yxjFZIX49F
2004-2011: #Pharma funding spent on phase 3 clinical trials increased by 36% http://t.co/T7N1oafHiP http://t.co/7p76rYWt0U
2004-2011: #Pharma funding spent on phase 3 clinical trials increased by 36% http://t.co/T7N1oafHiP http://t.co/7p76rYWt0U
#Migraine NIH research funding. No major disease is as underfunded. Almost off-the-charts. http://t.co/3bYdnTFkpW RT http://t.co/ZhnEuDin0K
2004-2011: #Pharma funding spent on phase 3 clinical trials increased by 36% http://t.co/T7N1oafHiP http://t.co/7p76rYWt0U